Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

BillionToOne, Inc. (BLLN) stock profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides a molecular counting platform designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations present in the tumor, including deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.

Key facts

SymbolBLLN
ExchangeNASDAQ
SectorHealthcare
IndustryMedical - Diagnostics & Research
CEOOguzhan Atay
Employees620
HeadquartersMenlo Park, CA, US
IPO2025-11-06
Websitewww.billiontoone.com

Explore BLLN on Vantafin

  • BillionToOne, Inc. Overview
  • BillionToOne, Inc. Financials
  • BillionToOne, Inc. News
  • BillionToOne, Inc. Events
  • BillionToOne, Inc. SEC filings
  • BillionToOne, Inc. Insider transactions
  • BillionToOne, Inc. Transcripts

Frequently asked questions

What does BillionToOne, Inc. (BLLN) do?
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides a molecular counting platform designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations present in the tumor, including deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Where is BLLN stock listed?
BillionToOne, Inc. trades under the ticker BLLN on NASDAQ.
How can I research BLLN's financials and filings?
Vantafin provides BillionToOne, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the BLLN profile.